Tuesday, February 04, 2020 4:19:26 PM
Fast track designation is intended to accelerate the development and review of experimental therapies aimed at treating serious or life-threatening conditions, with potential to address an unmet medical need. This designation includes frequent interactions with the FDA, eligibility for accelerated approval, priority review, and rolling submission of a new drug application to accelerate regulatory review.
Anavex Life Sciences is developing Anavex 2-73.
“With no currently approved agents to treat Rett syndrome, patients and their physicians have an urgent need for new therapeutic options,” Christopher U. Missling, PhD, president and CEO of Anavex Life Sciences, said in a press release. “We view this FDA Fast Track designation as continued support that Anavex 2-73 (blarcamesine) has the potential to address this unmet need.”
Anavex 2-73 is an oral, small-molecule activator of the sigma-1 receptor (S1R), a protein that plays a key role in protein folding. By activating S1R, Anavex 2-73 is designed to reduce the buildup of toxic misfolded proteins in nerve cells, as well as brain inflammation, oxidative stress, and mitochondrial impairment.
While mitochondria are cell compartments responsible for producing energy in the body, oxidative stress refers to an overproduction of oxidant molecules, known as reactive oxygen species, relative to the levels of antioxidant defenses in the body.
The FDA’s decision to grant fast track status to Anavex 2-73 was based on preliminary data from a Phase 2 clinical trial, called RS-001 (NCT03758924), recently presented at the 6th Annual European Rett Syndrome Conference in Finland. The study is still recruiting patients in the U.S.
Early findings from the first six patients on daily Anavex 2-73 over seven weeks showed that treatment led to significant improvements in the overall ability to function, assessed by the Clinical Global Impression Scale- Improvement, and lessened symptom severity as assessed by the Rett Syndrome Behavior Questionnaire.
Treatment also lowered the levels of the neurotransmitter glutamate and raised the levels of another neurotransmitter called gamma-aminobutyric acid (GABA) in the blood.
Neutransmitters are molecules that allow nerve cells to communicate. Some make nerve cells more likely to fire an electrical signal and are considered excitatory (glutamate), while others make cells less likely to fire and are inhibitory (GABA). The balance between excitatory and inhibitory neural signals is the basis of communication between nerve cells in the brain, and is disrupted in patients with Rett.
RS-001 is one of three trials — with AVATAR (NCT03941444) in Australia and EXCELLENCE — that form Anavex’s Rett Syndrome program. EXCELLENCE will enroll participants in Australia, with additional clinical sites planned to open globally in the future. The study will compare Anavex 2-73 with a placebo.
Anavex is also exploring the therapy’s potential to treat Parkinson’s and Alzheimer’s and has received a U.S. patent (No. 10,426,754) covering treatment of Alzheimer’s with Anavex 2-73. More recently, the company received a second U.S. patent (No. 10,507,196) covering treatment of Rett syndrome, multiple sclerosis, Angelman syndrome, cerebral palsy, and autism spectrum disorders.
The therapy previously received orphan drug and rare pediatric disease designations from the FDA for treating Rett syndrome.
Joana Carvalho, PhD
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM